SCHEMBL14865758

SCHEMBL14865758

CN1CCN(Cc2ccc(-c3nnc(-c4cncc(-c5ccnc(C(C)(C)C#N)c5)n4)o3)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.42
KIT P10721 2/20 0.39
ABL1 P00519 2/20 0.39
ABL2 P42684 1/20 0.39
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
KCNH2 Q12809 2/20 0.37
MCHR1 Q99705 1/20 0.37
PRKCQ Q04759 2/20 0.36
PRKCD Q05655 2/20 0.36
TNIK Q9UKE5 4/20 0.36
MAP3K11 Q16584 3/20 0.36
IKBKE Q14164 2/20 0.36
TBK1 Q9UHD2 2/20 0.36
CHKA P35790 1/20 0.36
CHEK1 O14757 1/20 0.35
RAF1 P04049 1/20 0.35
BRAF P15056 1/20 0.35
TGFBR1 P36897 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14865728 0.87 CHEK1 (0.50) IKBKETBK1CHEK1RAF1BRAF
SCHEMBL14866885 0.87 ATR (0.49) AXL
SCHEMBL14865610 0.83 ATR (0.41) RAF1BRAFMAPK1
SCHEMBL14865651 0.82 ATR (0.34) RAF1BRAF
SCHEMBL14865648 0.82 LTA4H (0.43) TLR9TLR7KCNH2PRKCQPRKCD
SCHEMBL14865757 0.81 RAF1 (0.41) CHEK1RAF1BRAFCYP3A4
SCHEMBL14865759 0.80 KDM4E (0.35) KCNH2MCHR1RAF1BRAFCYP3A4
SCHEMBL14865819 0.80 RAF1 (0.44) RAF1BRAFCYP3A4MAPK1
SCHEMBL14865685 0.79 ATR (0.43) KCNH2CHEK1RAF1BRAFTGFBR1
SCHEMBL14865751 0.79 RAF1 (0.36) RAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130095193-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130095193-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 AXL 805/4885KIT 1410/4885ABL1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.